← Eichor
Study identifier: NCT05610865 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers

Condition: Diabetic Foot Ulcer · Diabetes Mellitus · Diabetic Foot  ·  Sponsor: University of the Punjab

PhasePhase 1
Planned participants28
Who can joinAll sexes, 20 Years to 60 Years
Healthy volunteersNo

About this study

The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will increase the pragmatic potential of both types of cells as PRP is rich in survival and chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety of its use in diabetic patients and will unveil the more effective therapeutic option for treatment of foot ulcer wounds.

This description comes directly from the study's public registry record.

Talk to the study team

Azra Mehmood, PhD  ·  +92-333-4107008  ·  azra_mehmood@hotmail.com

Amna Arif, M.Phil.  ·  +92-333-4161068  ·  amnaarif.qureshi@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Stem Cell Laboratory, Jinnah Burn and Reconstructive Surgery Center (JB&RSC)Lahore, Punjab Province, PakistanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05610865